New Invention Profile
| Publication No: | IN202411038350 [India] | Application No: | IN202411038350 |
| Title: | Purine-based phthalazinones as dual parp and MTOR inhibitors and use thereof | ||
| Publication Date: | 28-11-2025 | File Date: | 15-05-2024 |
| Inventor(s): | Indranil Chatterjee; Saumya Ranjan Satrusal; Biswajit Mandal; Arpita Banerjee; Sanjeev Meena; Arpon Biswas; Rabi Sankar Bhatta; Gautam Panda; Dipak Datta | ||
| IPC Classification: | A61P35/00, A61P43/00, C07D237/32, A61P25/00, A61P25/28 | ||
| Abstract: | Mitigating the multifactorial progression of cancer demands a multi-targeted therapeutic strategy. Although FDA-approved PARP inhibitors have shown clinical success, their efficacy is largely restricted to BRCA-mutated cancers. Emerging evidence suggests that mTOR inhibition can sensitize cancer cells to PARP inhibition. In light of this, we aimed to develop a first-in-class dual PARP–mTOR inhibitor capable of targeting both BRCA-deficient and BRCA-proficient cancers, thereby expanding the therapeutic horizon for a broader population of cancer patients. The invention relates to purine-based phthalazinones as dual PARP [Poly (ADP-ribose) polymerase] and mammalian Target of Rapamycin (m-TOR) inhibitors, process for the preparation and uses thereof as potential anticancer agents. |
||
CSIR-Central Drug Research Institute[CSIR-CDRI]
: director[at]cdri[dot]res[dot]in
:91-522-2772450
:https://www.cdri.res.in
: director[at]cdri[dot]res[dot]in
:91-522-2772450
:https://www.cdri.res.in
Industrial Applications
Chemistry, Chemical Processes Polymers [Chemistry, Chemical Processes]
Synhtesis Procesess [Drugs and Pharmaceuticals]